3.95
-0.01(-0.25%)
Currency In USD
| Previous Close | 3.96 |
| Open | 3.93 |
| Day High | 4.06 |
| Day Low | 3.91 |
| 52-Week High | 7.55 |
| 52-Week Low | 2.12 |
| Volume | 1.97M |
| Average Volume | 4.9M |
| Market Cap | 392.26M |
| PE | -5.64 |
| EPS | -0.7 |
| Moving Average 50 Days | 4.67 |
| Moving Average 200 Days | 4.62 |
| Change | -0.01 |
If you invested $1000 in Aquestive Therapeutics, Inc. (AQST) since IPO date, it would be worth $246.11 as of February 22, 2026 at a share price of $3.95. Whereas If you bought $1000 worth of Aquestive Therapeutics, Inc. (AQST) shares 5 years ago, it would be worth $730.13 as of February 22, 2026 at a share price of $3.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Feb 20, 2026 12:00 PM GMT
Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeuti
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
GlobeNewswire Inc.
Feb 02, 2026 12:00 PM GMT
Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit i